v3.26.1
Marketable Securities
3 Months Ended
Mar. 31, 2026
Marketable Securities [Abstract]  
Marketable Securities
(6) Marketable Securities
 
Based upon the Company’s intent and ability to hold its U.S. Treasury securities to maturity, such securities have been classified as held-to-maturity and are carried at amortized cost, which approximates fair market value. Maturities on these U.S. Treasury security holdings range from 19 to 25 months from the date of purchase. Accrued bond interest receivable as of March 31, 2026 and December 31, 2025 was $96,197 and $97,024, respectively, and is included in other current assets on the Condensed Balance Sheets.
 
The tables below summarize the Company’s cost and fair value of marketable securities as of March 31, 2026 and December 31, 2025, respectively, as follows:
 
             
       March 31, 2026     
    Amortized Cost     Gross Unrealized Gain     Fair Value  
Held-to-maturity securities
              
U.S. Treasury securities
 $12,651,204   $37,796   $12,689,000 
 
   
December 31, 2025
 
   
Amortized Cost
   
Gross Unrealized Gain
   
Fair Value
 
Held-to-maturity securities
              
U.S. Treasury securities
 $12,615,881   $73,119   $12,689,000 
 
Maturities of marketable securities as of March 31, 2026 and December 31, 2025, respectively, are as follows:
 
    March 31,
2026
    December 31,
2025
 
           
Held-to-maturity securities:
         
Due in one year or less
$11,680,204  $10,618,881 
Due in 12 – 24 months
  971,000    1,997,000 
           
   $12,651,204   $12,615,881 
 
The Company’s investments in marketable securities consist of investments in U.S. Treasury securities. Market values were determined for each individual security in the investment portfolio.
 
Management evaluates securities for other-than-temporary impairment at least on an annual basis, and more frequently when economic or market concerns warrant such evaluation. Consideration is given to (1) the length of time and the extent to which the fair value has been less than cost, (2) the financial condition and near-term prospects of the issuer, and (3) the intent and ability of the Company to retain its investment in the issuer for a period of time sufficient to allow for any anticipated recovery in fair value. Management has determined that no other-than-temporary impairment exists as of March 31, 2026.